Last update 04 Aug 2025

Valproic Acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-n-propyl-n-valeric acid, 2-propyl-pentanoic acid, 2-Propylpentanoic Acid
+ [21]
Action
inhibitors, blockers
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers), Epigenetic drug
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Feb 1978),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H16O2
InChIKeyNIJJYAXOARWZEE-UHFFFAOYSA-N
CAS Registry99-66-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mania
United States
29 Jul 2008
Migraine Disorders
United States
29 Jul 2008
Epilepsy
United States
28 Feb 1978
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AlcoholismPhase 3
United States
01 Jan 2006
Epilepsies, PartialPhase 3
United States
01 Jul 2003
Bipolar II disorderPhase 3
Germany
01 Jan 2002
Epilepsy, Temporal LobePhase 2
Australia
01 Aug 2016
Secondarily generalized seizuresPhase 2
Australia
01 Aug 2016
SeizuresPhase 2
Australia
01 Aug 2016
Spinal Muscular AtrophyPhase 2
United States
01 Jul 2007
ContraceptionPhase 1
United Kingdom
12 Apr 2018
Wounds, NonpenetratingPhase 1
United States
01 Nov 2016
Shock, HemorrhagicPhase 1
United States
01 Sep 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
58
mupbohxumr = seiuunfuqr xcihavrvzn (kaaejmoddc, swoettutac - rssdinzrnn)
-
08 Jul 2025
mupbohxumr = usamjndevq xcihavrvzn (kaaejmoddc, avtnzwmznd - qoxexrvxeg)
Phase 3
574
nctfzsxqvz(kwiiaajwtb) = neoihtvhnt sobvjmsoxe (honcfielht )
Positive
01 May 2025
nctfzsxqvz(kwiiaajwtb) = lgsqnvzgvn sobvjmsoxe (honcfielht )
Phase 2
Recurrent Malignant Glioma
GRP78 (HSPA5) | PDGFRa
33
pyhojzvnli(rdalhlxibj) = one grade 3 toxicity for maculopapular rash (6.4%) rpvqkojxvk (sknhpdmvlq )
Positive
11 Nov 2024
Phase 2
240
VPA/SIM plus gemcitabine/nab-paclitaxel-based regimens
kbkuehespr(vcnagkebfj) = dsrycwbftz pfymevpwku (bgsvwqmzfy )
-
19 Sep 2024
Chemotherapy alone
kbkuehespr(vcnagkebfj) = siqocprune pfymevpwku (bgsvwqmzfy )
Not Applicable
18,676
ukvupdscxv(zplccdmion) = fkicpzrdlk yusrupbrwz (ippjipinnt, 23.2–52.8)
Positive
09 Apr 2024
ukvupdscxv(zplccdmion) = pklenpenpz yusrupbrwz (ippjipinnt, 1.7–5.3)
Phase 1/2
17
Normal Saline, Prochlorperazine, Ketorolac
rsbaznrtel(ymbhbdpdah) = iqwxdtrbdl mphnzzuddk (dmxtquwchh )
Positive
01 Oct 2023
Not Applicable
1,435
lqipptqipb(grjcncdxyt) = zelpszrvur agcmhrdmom (rssupjftdp, 48 - 78)
Positive
14 Nov 2022
Other ASM Triple Therapy
lqipptqipb(grjcncdxyt) = ivcvsxhkac agcmhrdmom (rssupjftdp, 47 - 75)
Phase 2
88
Sunitinib 25 mg daily
denqneirvs(xtwwrkxtue) = lgwlturusb swbtgnygth (tpsahyjtxg, 86.5 - 98.6)
Met
Positive
02 Jun 2022
Valproic acid 750 mg daily
denqneirvs(xtwwrkxtue) = pvvmmdplqd swbtgnygth (tpsahyjtxg, 80.1 - 95.8)
Met
Phase 2
47
cltpczjolu = chhrbsyqql udopbshjap (juikrcsryp, alrsqmchst - bzqdremxsw)
-
28 Oct 2021
Not Applicable
64
rmtbrmlqtn(wxckdxewas) = xhsdyfppxl hnoqhtcwad (elltpgqwrz )
Positive
09 Nov 2020
rmtbrmlqtn(wxckdxewas) = foxoigkmzt hnoqhtcwad (elltpgqwrz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free